Hałasa Józef, Hałasa Maciej
Pol Merkur Lekarski. 2002 Feb;12(68):140-2.
When first used, immunotherapy was applied to treatment of infectious diseases. Its high effectiveness gave an impulse to introduce this method in the treatment of allergic diseases, including bronchial asthma. In contrast to pharmacological treatment which treats only the symptoms in allergies, immunotherapy is presently considered to be the only causative treatment. Several conditions have to be fulfilled to obtain the effect of such treatment. Appropriate patients selection, use of the etiologically correct vaccine and continuing the treatment throughout several seasons are the conditions for the therapeutic success. In nonatopic intrinsic asthma or in atopic asthma complicated by bacterial infections the use of autologic or polyvalent (standard) bacterial vaccine should be considered. Because immunotherapy brings a risk of serious side effects such as anaphylactic reaction, only allergy specialist should be entitled to decide of the introduction of such treatment and to supervise its course.
免疫疗法首次应用于传染病的治疗。其高效性促使人们将该方法引入包括支气管哮喘在内的过敏性疾病的治疗中。与仅治疗过敏症状的药物治疗不同，免疫疗法目前被认为是唯一的病因治疗方法。要获得这种治疗效果，必须满足几个条件。选择合适的患者、使用病因正确的疫苗以及在几个季节中持续进行治疗是治疗成功的条件。在非特应性内源性哮喘或合并细菌感染的特应性哮喘中，应考虑使用自体或多价（标准）细菌疫苗。由于免疫疗法存在严重副作用的风险，如过敏反应，只有过敏专科医生才有资格决定是否采用这种治疗方法并监督其过程。
